Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.7326/0003-4819-47-5-956 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exploring Denosumab in the Treatment of Giant Cell Tumors: Clinical Evidence and Controversies.
J Craniofac Surg
November 2024
Department of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, Miami, FL.
Giant cell tumors (GCTs) are benign but locally aggressive bone neoplasms that primarily affect skeletally mature individuals. They are characterized by a tendency for recurrence and being associated with significant morbidity. Traditional treatment has focused on surgical resection; however, the role of medical therapies, such as Denosumab, a bone anti-resorptive drug, which has been Food and Drug Administration (FDA)-approved for unresectable GCTs since 2013, recently has gained prominence.
View Article and Find Full Text PDFClinical simulation training for first responders in pediatric emergencies with family interaction: a scoping review.
Rev Bras Enferm
January 2025
Universidade Federal de Mato Grosso do Sul. Campo Grande, Mato Grosso do Sul, Brazil.
Objective: To map studies on clinical simulation training directed at first responders during pediatric emergencies, focusing on interaction with families.
Methods: A scoping review based on the guidelines of the JBI Manual for Evidence Syntheses and reported according to the PRISMA-ScR checklist, covering eight databases and gray literature, without time or language restrictions.
Results: The ten selected studies indicated that most publications were from the United States.
Construction of a bundle for the safety of patients with mental disorders during hospitalization.
Rev Bras Enferm
January 2025
Universidade Federal de São João del-Rei. Divinópolis, Minas Gerais, Brazil.
Objective: to develop a bundle for the safety of psychiatric patients during hospitalization.
Methods: a methodological study conducted in two stages. In the first, a comprehensive literature review was developed through a scoping review and conducted to examine evidence on the safety of psychiatric patients during hospitalization.
Proper timing or ERCP and cholecystectomy on acute cholecystitis: a systematic review and meta-analysis.
Acta Cir Bras
January 2025
Instituto de Ensino, Pesquisa e Inovação - Liga Contra o Câncer - Natal (RN) - Brazil.
Purpose: To determine if endoscopic retrograde cholangiopancreatography (ERCP) should be performed with surgery or as a different step, on acute cholecystitis, and which strategy has the least complications and morbimortality.
Methods: Various databases (PubMed, Embase, Scopus, Web of Science, Science Direct, Cochrane Central Register of Controlled Trials, CINAHL, Latin American and Caribbean Health Sciences Literature, clinical trials, Google Scholar) were searched for randomized trials comparing the different timings for ERCP and cholecystectomy. No language or time restrictions were applied.
Bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) for multidrug- or rifampin-resistant tuberculosis: a systematic review.
J Bras Pneumol
January 2025
. Instituto de Doenças do Tórax - IDT - Faculdade de Medicina, Universidade Federal do Rio de Janeiro - UFRJ - Rio de Janeiro (RJ) Brasil.
Objective: To evaluate the available evidence comparing the use of the bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) regimen for 6 months with that of standard-of-care regimens for patients with multidrug-resistant or rifampin-resistant tuberculosis (MDR/RR-TB).
Methods: This was a systematic review of clinical trials comparing the use of the BPaLM regimen with the standard of care in patients with MDR/RR-TB. The main outcome measure was an unfavorable endpoint (a composite of death, treatment failure, treatment discontinuation, loss to follow-up, and recurrence), and secondary outcome measures included adverse events and serious adverse events.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!